https://me-pedia.org/wiki/CHROME CHROME (Case History Research on ME) was a registered charity founded in 1994 which aimed to identify as many severely disabled myalgic encephalomyelitis sufferers as possible in the UK and to monitor the course of their illness over a period of ten years.[1] 1998, Severe CFS/ME of Juvenile Onset— A Report from the CHROME Database[2](Abstract) 2009, Severe ME/CFS in Adults-A report from the CHROME Database[3](Full Text) https://www.researchgate.net/public...S_in_Adults-A_report_from_the_CHROME_Database Corpus ID: 80363036 Severe ME/CFS in adults - a report from the CHROME database https://www.semanticscholar.org/pap...ddon/328aab20326b4d22c5cf6a25e2da3fe34cd8af1b
Severe ME/CFS in adults - a report from the CHROME database D. Pheby, P. Sneddon, I. Heinrich Published 2010 Medicine, Psychology BACKGROUND: Case History Research on ME (CHROME) was established in 1994 to undertake research on severely affected patients. Since 1995 CHROME has collected data on volunteers with severe ME/CFS. All are medically diagnosed, conform to Fukuda criteria, are or were house-bound, and ill for at least two years. Participants complete initial and annual follow-up questionnaires, and report their condition at onset of illness, a year previously, on recruitment, and annually thereafter. METHOD: We report symptom severity and ability to undertake activities of daily living in 324 participants recruited between 1995 and 1998, their evolution through time, and, for later onset (age 17+) subjects, changes occurring between recruitment and the latest questionnaire. Significance was assessed using the McNemar test or its binomial equivalent. RESULTS: For most features, subjects deteriorated between onset and recruitment, with subsequent improvement, often slow and uneven, among later onset cases. Complete recovery was unusual. There were marked individual variations, and many subjects remained severely incapacitated or deteriorated. All features examined were more prevalent and severe in patients with a younger age of onset. Age at onset was bimodal, with peaks at 11-20 and 31-40. Most subjects, at recruitment, had been ill for 2-10 years. The proportion of early onset cases rose significantly in the mid-1980s. CONCLUSIONS: Caution is necessary in interpreting the results, given problems of self- selection, recall bias, and subjective interpretations of symptom ratings. It is unclear whether the reported trends are inevitable features of ME/CFS, or perhaps due to poor management at the outset.